Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising

In addition to a $140 million series D, GRIN Therapeutics has signed a global licensing deal for the epilepsy disorder drug radiprodil worth $50 million upfront.